The balance sheet shows severe deterioration, with shareholders' equity plummeting to $3.6 million and a debt-to-equity ratio rising to 1.91 as of 2026Q1.
| Total Current Assets | 5.15M | 11.58M | 51.7M | 100.95M | 120.4M | 178.37M | 17.13M | 15.73M |
| Cash & Short-Term Investments | 3.68M | 9.79M | 49.1M | 98.18M | 116.21M | 173.51M | 16.87M | 15.48M |
| Cash Only | 1.41M | 2.57M | 9.74M | 52.82M | 116.21M | 173.51M | 16.87M | 2.16M |
| Short-Term Investments | 2.27M | 7.22M | 39.36M | 45.35M | 0 | 0 | 0 | 13.32M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.47M | 1.79M | 2.6M | 2.78M | 4.2M | 0 | 0 | 255K |
| Total Non-Current Assets | 7.43M | 8M | 16.02M | 18.91M | 19.89M | 3.31M | 663K | 630K |
| Property, Plant & Equipment | 6.73M | 7.03M | 15.04M | 17.86M | 18.86M | 2.25M | 445K | 482K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 936K | 0 | 0 | 0 | 936K | 0 | 345.19M | 0 |
| Other Non-Current Assets | 702K | 965K | 985K | 1.05M | 92K | 1.05M | -344.97M | 148K |
| Total Assets | 12.59M | 19.58M | 67.72M | 119.86M | 140.29M | 181.68M | 17.79M | 16.36M |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Asset Growth % | -268.02% | -71.08% | -43.5% | -14.56% | -22.78% | 921.36% | 8.7% | - |
| Total Current Liabilities | 3.35M | 3.9M | 7.67M | 7.28M | 8.39M | 6.25M | 814K | 622K |
| Accounts Payable | 1.03M | 894K | 1.17M | 1.26M | 1.73M | 1.5M | 373K | 203K |
| Days Payables Outstanding | 393.28 | 228.99 | 201.99 | 247.66 | - | - | - | - |
| Short-Term Debt | 1.16M | 1.95M | 0 | 0 | 16K | 647K | 47K | 47K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.16M | 1.06M | 3.97M | 4.06M | 0 | 0 | 291K | 372K |
| Current Ratio | 1.54x | 2.97x | 6.74x | 13.87x | 14.35x | 28.56x | 21.04x | 25.30x |
| Quick Ratio | 1.54x | 2.97x | 6.74x | 13.87x | 14.35x | 28.56x | 21.04x | 25.30x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 5.67M | 5.84M | 13.35M | 14.62M | 20.85M | 92.34M | 121K | 111K |
| Long-Term Debt | 5.67M | 0 | 0 | 0 | 0 | 691K | 63K | 111K |
| Capital Lease Obligations | 29.25M | 5.84M | 12.57M | 13.79M | 14.83M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | -12.07M | 0 |
| Other Non-Current Liabilities | 0 | 0 | 787K | 830K | 6.02M | 91.65M | 58K | 0 |
| Total Liabilities | 9.02M | 9.74M | 21.02M | 21.89M | 29.25M | 98.59M | 935K | 733K |
| Total Debt | 6.82M | 7.79M | 13.79M | 14.83M | 15.69M | 1.34M | 110K | 158K |
| Net Debt | 5.42M | 5.22M | 4.05M | -37.99M | -100.52M | -172.17M | -16.76M | -2M |
| Debt / Equity | 1.91x | 0.79x | 0.30x | 0.15x | 0.14x | 0.02x | 0.01x | 0.01x |
| Debt / EBITDA | -0.16x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.13x | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -2841.84x | 26.79x | -394.58x | -4328.33x | - |
| Total Equity | 3.57M | 9.84M | 46.7M | 97.97M | 111.05M | 83.09M | 16.85M | 15.63M |
| Equity Growth % | -312.02% | -78.93% | -52.33% | -11.78% | 33.64% | 393.03% | 7.81% | - |
| Book Value per Share | 0.53 | 1.66 | 7.93 | 20.13 | 26.15 | 25.80 | 4.92 | 2.86 |
| Total Shareholders' Equity | 3.57M | 9.84M | 46.7M | 97.97M | 111.05M | 83.09M | 16.85M | 15.63M |
| Common Stock | 17K | 17K | 17K | 17K | 13K | 12K | 9K | 1K |
| Retained Earnings | -253.45M | -246.12M | -195.94M | -132.71M | -61.64M | -66.8M | -31.59M | -18.72M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2K | 4K | 50K | 10K | 0 | 0 | -329.22M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity insolvency risk
According to recent quarterly filings, total assets have plummeted from $119.9 million in 2023Q4 to just $12.6 million in 2026Q1, signaling a severe and accelerating contraction of the company's resource base as it struggles to fund its ongoing research and development activities without any offsetting revenue.
The consistent decline in total assets reflects a business model that is consuming its capital foundation to sustain operations. This trajectory suggests that the company is rapidly approaching a point where it will lack the necessary resources to continue its current development path without immediate external intervention.
Based on reported financial statements, the company's cash position has dwindled to a precarious $1.4 million as of 2026Q1, representing a massive decline from the $52.8 million held in 2023Q4 and leaving the firm with virtually no buffer against operational shocks or further development delays.
The current ratio of 1.54, while technically above parity, is misleading given the absolute low level of cash relative to the company's historical quarterly burn rates. Investors should monitor this closely, as the current liquidity profile appears insufficient to support the capital-intensive nature of medical device clinical trials.
As indicated by the latest balance sheet data, the debt-to-equity ratio has surged to 1.91 in 2026Q1 from a low of 0.15 in 2023Q4, illustrating that the company is increasingly reliant on debt financing even as its underlying equity base is being rapidly eroded by persistent net losses.
This shift toward higher leverage in a pre-revenue environment suggests a potential struggle to secure non-dilutive funding. The rising D/E ratio warrants further investigation into the terms of these obligations, as the company's ability to service this debt appears highly questionable given the lack of operational cash flow.
Data from recent SEC filings shows that shareholders' equity has collapsed to $3.6 million in 2026Q1 from $98.0 million in 2023Q4, a trend driven by the accumulation of $253.4 million in retained losses that effectively negate the value of the company's initial capital raises.
The rapid depletion of equity highlights the significant value destruction experienced by shareholders since the company's public debut. This trend suggests that future financing requirements will likely necessitate highly dilutive equity offerings, further pressuring the existing ownership structure.
While the company reports $6.7 million in net property, plant, and equipment as of 2026Q1, the lack of commercial revenue suggests these assets may be subject to significant impairment risk if the Version 2.0 system fails to achieve regulatory clearance or market adoption.
The reliance on specialized manufacturing equipment for a product that has yet to reach the market creates a potential valuation trap. If the company is forced to pivot or liquidate, the recoverable value of these assets may be substantially lower than their current carrying value on the balance sheet.
Quick answers to the most common questions about buying RBOT stock.
As of 2025, Vicarious Surgical Inc. (RBOT) had total assets of $19.6M including $11.6M in current assets.
Vicarious Surgical Inc. (RBOT) carries total debt of $7.8M, offset by $9.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Vicarious Surgical Inc. (RBOT) has total shareholders' equity (book value) of $9.8M ($1.66 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Vicarious Surgical Inc. (RBOT) reported a current ratio of 2.97x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.